Source comparison
BPC-157 for Golfers Elbow Research: Full Evidence Comparison
Rat tendon transection model (2021) 40 rats BPC-157 10 mcg/kg daily × 14 days Tensile strength, histology 35% faster tensile strength recovery; 40–60% reduction in TNF-α, IL-6 Animal model; acute injury, not chronic tendinopathy Human case series (2022, Croati
This comparison does not assign a generated winner or score.
- Rat tendon transection model (2021)
- 40 rats
- BPC-157 10 mcg/kg daily × 14 days
- Tensile strength, histology
- 35% faster tensile strength recovery; 40–60% reduction in TNF-α, IL-6
- Animal model; acute injury, not chronic tendinopathy
- Human case series (2022, Croatia)
- 38 patients
- BPC-157 250–500 mcg localized injection, 4–6 weeks
- DASH score, VAS pain, ultrasound
- 68% functional improvement; mean DASH improvement 22 points
- No placebo control; small cohort; short follow-up
- In vitro fibroblast study (2019)
- Lab-cultured cells
- BPC-157 1–10 µg/mL
- Cell migration rate, FAK phosphorylation
- 28% faster migration; upregulated FAK signaling
- In vitro only; doesn't model tissue-level healing
- Observational sports clinic data (2023, Germany)
- 52 athletes
- BPC-157 200 mcg systemic daily × 6 weeks
- Return to sport timeline, pain scores
- Mean return to sport 4.2 weeks vs 8.1 weeks historical controls
- No randomization; self-selected sample
- Professional Assessment
- The strongest evidence for BPC-157 in tendon healing comes from controlled animal models showing reproducible improvements in collagen synthesis and inflammatory modulation. Human data is limited to case series and observational cohorts without placebo controls. The peptide shows biological plausibility and consistent directional effects, but lacks the evidentiary standard required for clinical recommendation. Use remains investigational.